Literature DB >> 19497378

Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET.

S Behnke1, U Schroeder, U Dillmann, H G Buchholz, M Schreckenberger, G Fuss, W Reith, D Berg, C M Krick.   

Abstract

Transcranial ultrasound (TCS) has been shown to reveal hyperechogenicity of the substantia nigra (SN) in Parkinsonian patients and in about 10% of healthy controls. It is hypothesized that SN hyperechogenicity in healthy subjects is a vulnerability marker for idiopathic Parkinson's disease (IPD). Although there is strong evidence that the echomarker results from increased local iron content, the exact pathophysiological mechanisms remain incompletely understood. Thus, prognostic impact can only be estimated. We examined 14 subjects with SN hyperechogenicity (SN+) (7 IPD patients and 7 controls) and 7 healthy controls without the echomarker (SN-) by a magnetic resonance imaging method (MRI; T2 relaxation times) known to reveal tissue inhomogeneity following abnormal iron content and by F-Dopa PET to assess nigrostriatal function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19497378     DOI: 10.1016/j.neuroimage.2009.05.072

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  14 in total

Review 1.  Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: no.

Authors:  Uwe Walter
Journal:  J Neural Transm (Vienna)       Date:  2010-12-29       Impact factor: 3.575

Review 2.  [Early recognition of Parkinson's disease. Objectifiable non-motor symptoms and biomarkers].

Authors:  B Mollenhauer; F Sixel-Döring; A Storch; C Schneider; R Hilker; E Kalbe
Journal:  Nervenarzt       Date:  2013-08       Impact factor: 1.214

Review 3.  Developments in the role of transcranial sonography for the differential diagnosis of parkinsonism.

Authors:  Andrea Pilotto; Rezzak Yilmaz; Daniela Berg
Journal:  Curr Neurol Neurosci Rep       Date:  2015-07       Impact factor: 5.081

Review 4.  Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies.

Authors:  Adriane Gröger; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2012-08-09       Impact factor: 3.575

5.  Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites.

Authors:  R Saunders-Pullman; D Raymond; A J Stoessl; D Hobson; K Nakamura; T Nakamura; S Pullman; D Lefton; M S Okun; R Uitti; R Sachdev; K Stanley; M San Luciano; J Hagenah; R Gatti; L J Ozelius; S B Bressman
Journal:  Neurology       Date:  2012-02-15       Impact factor: 9.910

6.  Hand function is impaired in healthy older adults at risk of Parkinson's disease.

Authors:  Gabrielle Todd; Miranda Haberfield; Patrick L Faulkner; Caroline Rae; Michael Hayes; Robert A Wilcox; Janet L Taylor; Simon C Gandevia; Jana Godau; Daniela Berg; Olivier Piguet; Kay L Double
Journal:  J Neural Transm (Vienna)       Date:  2014-05-03       Impact factor: 3.575

7.  Substantia nigra echogenicity in hereditary ataxias with and without nigrostriatal pathology: a pilot study.

Authors:  Patricia Martínez-Sánchez; Rubén Cazorla-García; Irene Sanz-Gallego; Elisa Correas-Callero; Irene Pulido-Valdeolivas; Javier Arpa
Journal:  Cerebellum       Date:  2015-06       Impact factor: 3.847

Review 8.  Is there a need to redefine Parkinson's disease?

Authors:  Philipp Mahlknecht; Werner Poewe
Journal:  J Neural Transm (Vienna)       Date:  2013-05-29       Impact factor: 3.575

9.  Clinical, genetic, and brain sonographic features related to Parkinson's disease in Gaucher disease.

Authors:  Tobias Böttcher; Arndt Rolfs; Bianca Meyer; Annette Grossmann; Daniela Berg; Peter Kropp; Reiner Benecke; Uwe Walter
Journal:  J Neurol       Date:  2013-06-29       Impact factor: 4.849

10.  Substantia nigra hyperechogenicity in healthy controls: a [¹⁸Fluoro] Dopa-PET follow-up study.

Authors:  Ute Schroeder; Stefanie Behnke; Hans-Georg Buchholz; Klaus Fassbender; Matthias Schreckenberger; Daniela Berg
Journal:  J Neurol       Date:  2013-04-07       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.